GTx Announces Poster Presentation On The Prevalence And Impact Of Hypogonadism In Cancer Patients With Muscle Wasting From Its Phase IIb Enobosarm Clinical Trial At The Endocrine Society’s 2012 Annual Meeting
GTx, Inc. (Nasdaq: GTXI) announced today that Dr. Adrian Sandra Dobs, Director, John Hopkins Clinical Research Network Professor of Medicine and Oncology at the John Hopkins University School of Medicine, will present her abstract on the “Prevalence and Impact of Hypogonadism in Cancer Patients with Muscle Wasting in a Phase IIb Enobosarm Trial” in a poster presentation during the 2012 Annual Meeting of the Endocrine Society. Dr. Dobs will deliver her presentation of Poster Number SUN-261 at 1:30 – 3:30 pm Central Daylight Time on June 24, 2012 during the Endocrine Society’s Annual Meeting at the George R. Brown Convention Center in Houston, Texas. Enobosarm is a selective androgen receptor modulator which binds to the androgen receptor and is designed to deliver the beneficial effects of androgens while minimizing unwanted clinical side effects. GTx conducted its Phase IIb clinical study of enobosarm in 159 cancer patients (average age of 66 years) with non-small cell lung cancer, colorectal cancer, non-Hodgkins lymphoma, chronic lymphocytic leukemia or breast cancer in 35 sites in the United States and Argentina. Participants were randomized to receive placebo, 1 mg or 3 mg oral tablet of enobosarm once daily for 16 weeks. Average reported weight loss prior to entry among all subjects was 8.8%, and subjects were allowed to have standard chemotherapy during the trial. The drop-out rate during the trial was 33%. The study met its primary endpoint of absolute change in total lean body mass (muscle) compared to placebo after 16 weeks of treatment. GTx is conducting two pivotal Phase III clinical trials in the United States, Europe and South America, evaluating a once daily 3 mg dose of enobosarm for the prevention and treatment of muscle wasting in patients with non-small cell lung cancer. More information about these two clinical studies can be found at www.gtxclinicaltrials.com. About GTx GTx, Inc., headquartered in Memphis, Tenn., is a biopharmaceutical company dedicated to the discovery, development and commercialization of small molecules that selectively target hormone pathways for the treatment of cancer, cancer supportive care and other serious medical conditions.